Product
Leronlimab
Aliases
Leronlimab (700mg), Pro140, PRO 140
4 clinical trials
1 abstract
7 indications
Indication
COVID-19Indication
CCR5Indication
MSSIndication
MetastaticIndication
Colorectal CancerIndication
Nonalcoholic SteatohepatitisIndication
Breast CancerClinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]Status: Completed, Estimated PCD: 2021-06-05
Clinical trial
A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)Status: Completed, Estimated PCD: 2021-12-29
Clinical trial
A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)Status: Withdrawn, Estimated PCD: 2023-05-27
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)Status: Completed, Estimated PCD: 2020-07-21